

## Sprint Bioscience appoints Scientific Advisory Board

**Sprint Bioscience AB (publ) today announces that the company strengthens its expertise in oncology and preclinical research by appointing a Scientific Advisory Board (SAB) to support in the development of new innovative cancer programs. The Board consists of the three leading cancer experts Professor Gunilla Enblad, Professor Robert J DeVita and Professor Lewis C. Cantley.**

"We are very pleased that we have succeed to attract some of the world's leading cancer experts. Their solid experience from academia and industry together with their deep expertise in preclinical research will be a great asset to us, both in specific projects and in terms of the overall strategy. In parallel with the work of our newly formed scientific advisory board, our collaborations with the academy continue, including the collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet," said Erik Kinnman, CEO of Sprint Bioscience.

The Scientific Advisory Board consists of:

**Gunilla Enblad** – Professor of oncology at Uppsala University since 2013 and chief physician at Uppsala University Hospital. Her research areas include clinical and tumor biological studies of malignant lymphomas, as well as immunotherapy including clinical studies of CAR T cells. Since 2019, she is chairman of the Swedish CAR T-cell group and is also a scientific advisor to XNK-therapeutics and Elicera Therapeutics. She is a member of the board of the Cancer Foundation and the Department of Immunology, Genetics and Pathology at Uppsala University. Since 2017, she is also a member of the Royal Swedish Society of Science in Uppsala.

**Robert J DeVita** – Principal Consultant of RJD Med Chem and Drug Discovery Consulting LLC since 2013. He has over 30 years of drug discovery and development experience working in biotechnology, pharmaceutical industry, and academia. At Merck Research Laboratories, he was Director of Medicinal Chemistry and led 6 different programs that delivered drug candidates for further clinical development several which reached human clinical trials. He has also been Vice President, Chemistry at Agios, a company focused on early drug development in oncology. For the past 10 years, he has run a consulting company in medicinal chemistry and supported other client companies in all phases of drug development, including IP strategy and due diligence in connection with licensing deals. He is also a member of the Medicinal Chemistry Division of the American Chemical Society, serving in a variety of leadership roles.

**Lewis C. Cantley** – Professor at the Dana Farber Cancer institute. He is a cell biologist and biochemist who has made groundbreaking discoveries in the area of cancer metabolism. Among his most notable contributions is the discovery and study of the enzyme PI-3 kinase, which is important in diseases like cancer and diabetes. He was previously the Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. He has also held positions as Professor at the Departments of Systems Biology and Medicine at Harvard Medical School and Director of Cancer Research at Beth Israel

Deaconess Medical Center in Boston. Prof Cantley is also co-founder of several biotech companies focused on oncology, including Agios Pharmaceuticals, Petra Pharma and Volastra Therapeutics. In 2016, he was elected Chairman of the Board of the Hope Funds for Cancer Research and has over the years received several scientific awards for his research.

**For further information, kindly contact:**

---

Erik Kinnman, CEO, Sprint Bioscience  
Tel: 08-411 44 55  
E-mail: [erik.kinnman@sprintbioscience.com](mailto:erik.kinnman@sprintbioscience.com)

**About Sprint Bioscience AB (publ)**

---

Sprint Bioscience develops small-molecule *first-in-class* drug programs with a focus on oncology. Using fragment-based drug discovery, the company develops drug programs in a time- and resource-efficient way and then license them to global pharma companies during the preclinical phase. The company has successfully entered into several license agreements amounting to a potential value of USD 747 million in milestone payments as well as income from royalties on sales. The company is headquartered in Stockholm with laboratories in Huddinge. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and is traded under the short name SPRINT. Further information is available on the company's website: [www.sprintbioscience.com](http://www.sprintbioscience.com).

Certified Advisor is FNCA Sweden AB; +46 (0) 8 528 00 399, [info@fnca.se](mailto:info@fnca.se), [www.fnca.se](http://www.fnca.se).

**Image Attachments**

---

[Erik Kinnman Vd Sprint Bioscience](#)

**Attachments**

---

[Sprint Bioscience appoints Scientific Advisory Board](#)